Pfizer

Trazimera

View Prices
  1. Home
    2.  / 
  2. Q Code
    3.  / Trazimera – Q5116

Manufacturer:

Pfizer

Name:

Trazimera

HCPCS Code Descriptor:

Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg

Category:

Q Code

HCPCS:

Q5116

NDC(s):

00069-0305-01, 00069-0308-01

Primary Type:

Oncology Biosimilar

Generic Status:

Single-Source

Route of Administration:

Intravenous

About:

Trazimera is an Oncology Biosimilar drug manufactured by Pfizer and administered via the Intravenous route of administration. The Q Code: Q5116 is aligned to the drug Trazimera.

Trazimera (trastuzumab) is a cancer drug that is used to treat certain types of breast and stomach cancers. This medication targets the HER2 protein of the cell and can be used in combination with other medications. Trazimera is manufactured by Pfizer and is biosimilar to the medication Herceptin (J9356). Trazimera is aligned to the Q Code Q5116 and has been aligned to this code since October 2019.

View Prices

Access Pricing and More By Registering

Register Now

HCPCS Added Date:

10/1/19

HCPCS Effective Date:

10/1/19

HCPCS Short Description:

Inj., trazimera, 10 mg

Billing and Coding Guide:

https://www.pfizeroncologytogether.com/files/TRAZIMERA_Billing_and_Coding_Guide.pdf

Patient Assistance:

Not Found